Francisco Guimerá
Hospital Universitario de Canarias
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Francisco Guimerá.
Pediatric Dermatology | 2011
Cristina Rodríguez-García; Sorahaya González-Hernández; Nuria Pérez-Robayna; Francisco Guimerá; E. Fagundo; Rosalba Sánchez
Abstract: There is a well‐established association of vitiligo with autoimmune conditions, and circulating autoantibodies to melanocytes have been demonstrated in the serum of patients with vitiligo. We present a case of repigmentation of vitiligo lesions in a girl with celiac disease after initiating a gluten‐free diet, which to our knowledge has not been reported.
Journal of The European Academy of Dermatology and Venereology | 2006
M Sáez; Marina Rodríguez-Martín; M Sidro‐Sarto; R Cabrera de Paz; F Rodríguez‐García; E Fagundo‐González; A Carnerero; Francisco Guimerá; M García‐Bustínduy; Roel Sánchez; A Martín Herrera; Antonio Noda
356 JEADV 2006, 20, 341–362
Journal of The European Academy of Dermatology and Venereology | 2004
M García‐Bustínduy; M Escoda; Francisco Guimerá; M Sáez; S Dorta; E. Fagundo; Rosalba Sánchez-González; Antonio Noda-Cabrera; R García‐Montelongo
Background An intermittent short course of cyclosporin A (CyA) therapy is a good choice in the treatment of severe psoriasis. Nevertheless, some severe or resistant patients might benefit from long‐term treatment. Adverse effects of long‐term use of CyA are investigated and the results are compared with the literature.
Journal of Cutaneous Pathology | 1999
M García‐Bustínduy; Hugo Álvarez-Argüelles; Francisco Guimerá; Candelaria Garcia-Castro; Rosalba Sánchez-González; Norberto Hernandez; Lucio Díaz-Flores; R García‐Montelongo
Only a few reports of primary cutaneous rhabdoid tumors have been published. We describe the case of a 3‐month‐old female patient who developed a rhabdoid type cutaneous sareomatoid neoplasm in her upper back, close to a benign myofibromatous proliferation of infancy. The lesion was studied both by light microscopy and immunohisto‐chemically. Flow cytometry was performed showing a DNA diploid profile of the malignant tumor. The pathological findings suggest a mesenchymal origin (hemangiopericytic or myofibroblastic type) for both tumors. The patient was surgically treated, but she died nine months later.
Journal of The European Academy of Dermatology and Venereology | 2006
Miguel Sáez-Rodríguez; Marina Rodríguez-Martín; A Carnerero-Rodríguez; M Sidro‐Sarto; F Rodríguez‐García; R Cabrera de Paz; Francisco Guimerá; M García‐Bustínduy; L. Diaz-Flores; Antonio Noda-Cabrera
1140 JEADV 2006, 20, 1133–1167
Journal of The European Academy of Dermatology and Venereology | 1998
M García‐Bustínduy; Antonio Noda; Rosalba Sánchez; Ma Jose Gonzalez de Mesa; Francisco Guimerá; R García‐Montelongo
To the Editor: We report the case of an 80-yearold man with localized scleroderma, treated successfully with PUVA therapy. The patient came to our office with progressive hardening of his abdominal skin. Clinical examination (Fig. 1) showed a large (25 cm in diameter) slightly erythematous plaque that could not be pinched and made it difficult for the patient to bend down. The lesion margins were rough, showing no lilac ring. Histological examination confirmed morphoea. The patient was classified as skin phototype IV. PUVA therapy began with 0.6 mgk, 42 mglday 8-methoxypsoralen and an initial UVA dose of 4 J/ cm2, which was gradually increased, weekly, to a maximal single dose of 18 J/cm2. Photochemotherapy was given once daily, three times a week from March to November 1996. Two months after the patient started treatment he felt better; in fact, soft areas could be seen inside the plaque. In November he was able to move around well, and photochemother-
Dermatology | 2009
Nuria Pérez-Robayna; Cristina Rodríguez-García; Sorahaya González-Hernández; Rosalba Sánchez; Francisco Guimerá; M Sáez
plaques, papules or nodules over the dorsa of joints, and GF usually appears as one or a few plaques on the face. In addition, eosinophils and plasma cells are prominent in GF, whereas neutrophils are plentiful in erythema elevatum diutinum [1] . GF is often quite resistant to therapy [2–6] . Topical calcineurin inhibitors may represent a useful alternative to topical corticosteroids for the treatment of a number of other inflammatory skin diseases different from atopic dermatitis [7] . We report a 90-year-old male patient without remarkable medical history who presented to our department with an asymptomatic lesion on the nasal tip. This lesion had been present for 6 months, and gradual enlargement had been observed. Physical examination revealed an oval, well-delimited, reddish yellow plaque, 2.5 ! 1.5 cm in size, with a smooth and brilliant surface. Focal telangiectasia and follicular openings were also found ( fig. 1 ). A biopsy specimen was obtained which showed a dense dermal polymorphous inflammatory infiltrate with neutrophils, lymphocytes, plasma cells and numerous eosinophils. A narrow grenz zone and a mild fibrosis area were also found. With these histological findings, a diagnosis of GF was made. Therapy with topical 0.1% tacrolimus ointment twice daily was started after he had not responded to the application of topical corticosteroids. Treatment was stopped after 3 months with remission lasting for 1 year. Only slight reddish coloration at the edges of the lesion remained ( fig. 2 ). No burning sensation was noted.
Journal of The European Academy of Dermatology and Venereology | 2006
M Sáez; Marina Rodríguez-Martín; A Carnerero; R Cabrera de Paz; Francisco Guimerá; M García‐Bustínduy; F Rodríguez‐García; M Sidro; A Martín Herrera; Antonio Noda
JEADV 2006, 20 , 461–488
Journal of The European Academy of Dermatology and Venereology | 2006
Marina Rodríguez-Martín; M Sáez; A Carnerero; M García‐Bustínduy; Francisco Guimerá; F Rodríguez García; R Cabrera de Paz; M Sidro; Roel Sánchez; A Martín Herrera; Antonio Noda
JEADV 2006, 20 , 999–1032
European Journal of Dermatology | 2014
Enrique Herrera-Acosta; Jorge Alonso Suarez-Perez; José Aguilera; Francisco J Gómez-García; R. Jiménez-Puya; Francisco Guimerá; Maria Victoria Mendiola; Enrique Herrera-Ceballos
The classic systemic treatments for psoriasis, such as cyclosporine, methotrexate and phototherapy, are limited by their accumulative toxicity [1] and the new generation of monoclonal antibody-based treatments is in trial. The concept of treatment survival is defined as the time for which a drug remains a suitable option for a given patient [2] and is considered a therapeutic success factor, depending on its efficacy, the presence of adverse events and patient satisfaction [3-5]. A few drug-survival [...]